Blue Cross Blue Shield - Tennessee Allergen Testing Coverage

Covered indications

Covered when ALL of the following apply:

Permitted uses of specific IgE in-vitro testing: a) In lieu of skin testing for an INITIAL allergy screen; b) When skin testing is contraindicated or when skin testing results are inconsistent with the history of an anaphylactic or other severe reaction and confirmation of sensitivity would impact treatment decisions (including evaluation of individuals with asthma, suspected allergen-induced chronic rhinitis, suspected food allergy, suspected insect venom allergy, or suspected allergy to specific drugs).

Based on clinical history, exam, and environment; see annual limit of 20 allergen-specific antibodies.

Clinical coverage criteria

Covered when testing aligns with clinical indications and professional society guidance

Clinical indication: Testing (SPT, serum sIgE, component testing, BAT) should be performed based on patient history, focused physical examination, pretest probability, geographic exposure, and clinician judgment; test results must be interpreted in clinical context and are not diagnostic alone.

AAAAl/ACAAI and WAO guidance support selective testing based on history and exposure.

Preferred modalities by context: SPT is first-line for many IgE-mediated conditions; in-vitro sIgE is preferred when skin testing is contraindicated (widespread skin disease, interfering medications, uncooperative patients, or heightened anaphylaxis risk). Component testing (e.g., Ara h 2) may be used selectively (e.g., when a single diagnostic test for peanut is desired); BAT may be used as a second-step test when SPT/sIgE are equivocal, particularly for peanut.

Selective use of component testing and BAT per society statements.

Tests to avoid/routinely not indicated: IgG and IgG subclass antibody tests for food allergy lack clinical relevance and should not be performed; avoid indiscriminate large panels of sIgE testing without focused clinical suspicion and avoid non-standardized tests for routine evaluation.

AAAAl/ACAAI and NIAID recommend against immunoglobulin G testing and indiscriminate IgE panels.

Indications for allergy testing

Covered when testing is directed by history and clinical context and used to answer a specific diagnostic or management question.

Appropriate indications: Testing is indicated for suspected IgE-mediated conditions including: asthma where perennial aeroallergen sensitivity is suspected; rhinitis/rhinosinusitis; eczema/atopic dermatitis with suspected IgE sensitization; suspected food allergy with temporal correlation to ingestion or anaphylaxis; suspected drug allergy; hymenoptera (insect) venom allergy; occupational exposures; and selected cases of chronic urticaria or less common disorders (e.g., eosinophilic esophagitis) where IgE sensitization is relevant.

Select tests and allergens based on history, exam, region, and exposures; results must be correlated clinically.

Not routinely indicated / low-value testing

Not routinely indicated when ALL of the following apply:

Inappropriate uses: Screening asymptomatic individuals; evaluation of non‑IgE food intolerance (e.g., IBS without allergic features); non‑specific cutaneous rashes or symptoms without atopic features; routine use of total serum IgE to diagnose food allergy; routine broad or indiscriminate multi‑allergen sIgE panels; and use of non‑standardized tests (eg, basophil histamine release/activation, lymphocyte stimulation, allergen‑specific IgG, cytotoxicity assays) for routine food allergy evaluation.

WAO and guideline summaries list these as not routinely indicated.

Peanut allergy evaluation

Special pediatric guidance for peanut introduction and testing:

Peanut testing consideration: For infants at increased risk (severe eczema and/or egg allergy), strongly consider peanut‑specific IgE measurement and/or skin prick testing prior to peanut introduction; testing for peanut sIgE may be the preferred initial approach in settings where SPT is not routinely available. Do not perform routine multiallergen food panels or add sIgE testing for foods other than peanut because of poor positive predictive value.

Based on NIAID addendum and AAP guidance recommending testing prior to peanut introduction in high‑risk infants.

The Antigen Leukocyte Antibody Test (ALCAT) is specifically listed as a test that DOES NOT MEET COVERAGE CRITERIA. ALCAT measures leukocyte responses to food antigens but has reported issues with reproducibility and lack of correlation with clinical allergy, and therefore is not considered a covered diagnostic modality for suspected allergy (see discussion of ALCAT reproducibility and clinical correlation).

Similarly, in-vitro testing of non-specific immunoglobulins (including non-specific or allergen-specific IgG and other immunoglobulins such as IgA, IgM, and IgD) is excluded from coverage for the evaluation of suspected allergy due to lack of evidence of clinical utility.

The Basophil Activation Test (BAT) using flow cytometry is also listed as DOES NOT MEET COVERAGE CRITERIA in this policy excerpt; although BAT is described in the literature as a functional research tool with potential diagnostic value in some studies, it is not an approved covered test in this policy segment and is excluded from routine coverage.

Professional society guidance referenced in this policy states that IgG and IgG subclass antibody tests for food allergy are not clinically relevant and should not be performed. These assays lack validation, sufficient quality control, and demonstrated clinical relevance for diagnosing IgE-mediated food allergy.

The policy reinforces that such IgG-based testing is not recommended in routine clinical evaluation of suspected food allergy and is identified among assays that DO NOT MEET COVERAGE CRITERIA.

The World Allergy Organization and related guidance note that skin prick testing (SPT) is not routinely indicated in a number of situations when there are no other supportive features of allergic disease. Examples include suspected food intolerance (non-IgE mediated conditions), chronic urticaria without a history suggesting an allergen trigger, non-specific cutaneous rashes without atopic features, non-specific respiratory symptoms to irritants, screening of asymptomatic individuals, and evaluation for non-allergic causes.

SPT must be interpreted in the clinical context by clinicians familiar with the patient history and relevant regional allergens; routine use of SPT for non-allergic presentations or indiscriminate screening is discouraged.

The policy advises against routine use of broad food allergen panel testing and non-standardized assays. Examples of discouraged technologies include multiplex microarray panels, bead-based epitope assays (e.g., VeriMAP), qualitative multi-allergen non-specific IgE screens, and other proprietary large panels offered by commercial laboratories.

These non-standardized or non-validated panel approaches are identified as tests that DO NOT MEET COVERAGE CRITERIA for routine food allergy evaluation because they lack sufficient evidence demonstrating clinical benefit and appropriate interpretation in isolation.

The policy cites literature and guidance that characterize certain assays and techniques as unproven diagnostic tests or unproven techniques in allergy diagnosis. Examples referenced in the bibliography include reviews and articles describing lack of validation or clinical utility for some proprietary or nonstandard tests.

Professional guidance (including Choosing Wisely statements and specialty society practice parameters) specifically recommends against performing unproven tests—such as indiscriminate IgG testing, non-standardized basophil mediator assays, and other non-validated diagnostics—in routine clinical practice.

The policy states that, except where specifically allowed (e.g., annual re-testing for food allergens in children to monitor for resolution), routine re-testing for allergies to the same allergens does not meet coverage criteria in the absence of a new clinical presentation. Re-testing should be prompted by a change in history, symptoms, or clinical circumstances that justify repeat testing.

Annual food re-testing in children/adolescents to monitor for remission is an explicit exception; otherwise, repeat testing without new clinical indication risks being considered not covered.

Routine measurement of total serum IgE for the diagnosis of food allergy is not recommended because total IgE has low positive predictive value for food allergy and is not diagnostic on its own. Professional guidance recommends focused use of specific IgE (SPT or serum sIgE) to targeted suspected foods rather than broad measurement of total IgE for food allergy diagnosis.

Total IgE measurement is, however, supported for specific indications noted in the policy—such as baseline total IgE for dosing of anti-IgE therapies (e.g., omalizumab) or evaluation for allergic bronchopulmonary aspergillosis—rather than for routine food allergy screening.

The policy clarifies that using total serum IgE alone to diagnose food allergy is not medically appropriate. In addition, the routine use of non-standardized tests (including basophil histamine release/activation, lymphocyte stimulation, allergen-specific IgG, cytotoxicity assays, and similar methods) for routine food allergy evaluation is considered not medically necessary and is discouraged.

Providers should rely on validated approaches—clinical history correlated with SPT or serum sIgE (and selective component testing when indicated)—rather than non-validated or nonstandardized assays for diagnosis and management decisions.

The referenced literature list includes sources addressing unproven diagnostic tests for food allergy and published discussions of unproven techniques in allergy diagnosis. These citations are provided to support the policy stance that certain assays lack sufficient evidence and should not be used in routine clinical practice.

Clinicians are directed to the listed references for detailed discussion and evidence reviews regarding the validity and limitations of various nonstandard diagnostic approaches.

Provider Actions, Documentation, and Billing Guidance

Documentation Required

Specific IgE testing limits and selection

Specific IgE testing is limited to 20 allergen-specific antibodies per member per year and should be reserved for directed testing based on the individual's history, physical exam, and environment. Use of specific IgE in-vitro testing as an initial screen is acceptable in lieu of skin testing when skin testing is contraindicated or infeasible, or when skin test results are discordant with a history of anaphylaxis or other severe reaction and confirmation would affect management.

Limit: 20 allergen-specific sIgE tests per year
Allergen selection must be based on focused history, exam, and environmental exposure

Note

Selective use of specific and component testing

Select specific and component testing (for example, Ara h 2 for peanut) based on clinical history and pretest probability. Component testing may be useful in situations such as confirming peanut allergy where pretest probability is high, but routine addition of component testing to SPT or sIgE to whole allergen is not recommended. Interpret component results within the clinical context; recognize varying sensitivity and predictive value across allergens.

Use component testing selectively when it will change clinical decision-making (e.g., Ara h 2 for peanut)
Avoid routine component testing in addition to SPT or whole-allergen sIgE

Documentation Required

Baseline total IgE for anti-IgE therapy

Obtain a baseline total serum IgE before initiating anti-IgE therapy (e.g., omalizumab/Xolair) when dosing is determined by pre-treatment total IgE and body weight. Do not use IgE levels measured during treatment to guide dosing, as total IgE rises during therapy and can remain elevated for up to one year after discontinuation.

Baseline total IgE required for dose determination of omalizumab
Do not re-measure IgE during treatment to adjust dose

Note

Prior authorization

No prior authorization requirement is specified in the excerpts provided for these tests. Check current payer-specific portals or policy pages for any local prior authorization rules that may apply.

Denial Risk

Denied / Not covered tests

The following tests DO NOT MEET COVERAGE CRITERIA and are denied: Antigen Leukocyte Antibody Test (ALCAT); in-vitro testing of allergen-specific IgG or non-specific IgG, IgA, IgM, and/or IgD for evaluation of suspected allergy; Basophil Activation Tests (BAT); bead-based epitope assays such as VeriMAP Peanut Dx; and qualitative multi-allergen non-specific IgE screens that do not identify specific allergens.

ALCAT — not covered
IgG / IgG subclass, IgA, IgM, IgD antibody testing for food allergy — not covered
BAT — not covered
Bead-based epitope assays (e.g., VeriMAP) — not covered
Non-specific multi-allergen qualitative IgE screens — not covered

Denial Risk

Not applicable tests (IgG and IgG subclass)

IgG and IgG subclass antibody tests for food allergy lack clinical relevance and validation and should not be performed; these tests do not meet coverage criteria. Routine or screening tests for allergy in the absence of symptoms (including IgG testing and other unproven assays) are not appropriate.

IgG and IgG subclass tests for food allergy — not applicable/not clinically relevant
Avoid routine screening in asymptomatic individuals

Denial Risk

Tests lacking clinical indication risk denial

Tests ordered without appropriate clinical indication or documentation risk denial. Examples include routine population screening for sensitization without symptoms, testing for suspected food intolerance without allergic history, non-specific screens without targeted allergens, and repeat testing for the same allergens in the absence of a new clinical presentation.

Routine screening without symptoms — high denial risk
Testing for suspected food intolerance without allergic history — high denial risk
Repeat testing for same allergens without new clinical change — not covered except as specified for children/adolescents

Documentation Required

LDT regulatory status and documentation

When documenting testing, indicate the regulatory status of the assay (FDA-cleared/approved versus laboratory-developed test [LDT]) and the CLIA complexity classification when applicable. LDTs are regulated under CLIA as high-complexity tests and are not FDA-cleared; their use may prompt payer review.

Document whether assay is FDA-cleared/approved or an LDT
Note CLIA complexity (e.g., high-complexity) for LDTs

Documentation Required

Required clinical documentation

Required clinical documentation must support test selection and include a focused history, physical exam findings, and environmental/occupational exposure relevant to the suspected allergen. Indicate why skin testing is not appropriate when sIgE is used instead (see contraindications) and provide documentation when testing will affect management decisions.

Focused history and physical to justify directed testing
Reason for choosing in-vitro testing over skin testing when applicable
Documentation that results will impact treatment or management

Documentation Required

Clinical selection and interpretation

Select and interpret tests based on the patient's history, age, region, exposures, and pretest probability. A positive specific IgE does not alone confirm clinical allergy; correlate results with symptoms and, when needed, use oral food challenge or specialist evaluation for definitive diagnosis.

Interpret sIgE and SPT results in clinical context — do not assume sensitization equals clinical allergy
Consider OFC or specialist input when diagnosis remains uncertain

Documentation Required

Required clinical justification

Provide focused clinical justification for directed testing: specify suspected IgE-mediated reaction, nature and timing of symptoms, severity (including any history of anaphylaxis), and how test results will influence management (e.g., immunotherapy, avoidance, emergency planning).

Document suspected IgE-mediated reaction and relevant symptom history
State how results will change treatment or management

Note

Testing sequence preference

Testing sequence preference: skin prick testing (SPT) is often the preferred first-line modality for aeroallergens based on accuracy, convenience, cost, and prompt results. Serum sIgE is an acceptable alternative when SPT is contraindicated or infeasible. In-vitro specific IgE testing may be used in lieu of skin testing for an initial screen when appropriate.

SPT preferred first-line for aeroallergens when feasible
Use serum sIgE when SPT contraindicated or infeasible
In-vitro sIgE acceptable as initial screen in selected situations

Step Therapy

Two-step diagnostic approach

Two-step diagnostic approaches (for example, performing BAT only after equivocal SPT or Ara h 2-sIgE) have been shown in studies to reduce the need for oral food challenges. Reserve second-line or specialized tests for cases where first-line testing is inconclusive and when the additional test will change management.

Consider BAT or other second-line tests only after equivocal first-line testing
Two-step approaches can substantially reduce oral food challenges in specialized settings

Note

Testing order preference

Testing order preference: for aeroallergens, choose SPT first when possible; consider intradermal testing as a second-line test when clinical suspicion remains high and SPT is negative. Use serum sIgE when skin testing is contraindicated (e.g., dermatographism, interfering medications, high anaphylaxis risk) or when patient factors prevent reliable skin testing.

Intradermal testing as second-line to exclude reactivity when suspicion high
Use serum sIgE if patients cannot safely undergo or reliably complete SPT

Definitions and Test Descriptions

Specific IgE (sIgE)

DefinitionImmunoassays measuring allergen-specific immunoglobulin E (sIgE) in serum to detect sensitization; presence of antibody confirms sensitization but clinical reactivity requires history or supervised challenge

When preferredUseful when skin testing is contraindicated (widespread skin disease, interfering medications, uncooperative patients) or when SPT cannot be performed

InterpretationsIgE and skin tests are not diagnostic alone; results must be interpreted with clinical context and pretest probability

Relation to total IgETotal IgE is usually unrelated to specific IgE levels and is of modest value as a general screen; total IgE testing is covered for select indications (e.g., omalizumab dosing)

Basophil activation test (BAT)

DefinitionAn ex vivo flow cytometry–based assay measuring basophil activation markers (e.g., CD63, CD203c) after allergen stimulation

Clinical potentialShown in studies to have high diagnostic accuracy for food allergy (notably peanut) and can reduce the need for oral food challenges when used as a second-step test

LimitationsClinical use limited by lack of standardization across laboratories, variable methodology, and need for quality assurance and validation

Preferred roleConsider as a second-step or adjunctive test when SPT/sIgE are equivocal or when skin testing is contraindicated

ALCAT

DefinitionAntigen Leukocyte Antibody Test (ALCAT) stimulates leukocytes to assess food/immune reactions regardless of antibody pathway

Evidence concernsPublished studies report poor reproducibility and lack of correlation with clinical evidence of allergy

Coverage stanceALCAT does NOT MEET COVERAGE CRITERIA

SPT (skin prick test)

DefinitionIn vivo method introducing standardized extracts into the skin to detect allergen-specific IgE; rapid, low-cost, and commonly used

PerformanceAverage pooled sensitivity around 85% and often selected as first-line for aeroallergen diagnosis

When contraindicatedNot appropriate for patients with uncontrolled severe asthma, on beta-blockers, pregnancy, or when medications/skin conditions interfere; sIgE is alternative

Component/epitope testing (e.g., Ara h 2, BBEA)

DefinitionIn vitro assays measuring IgE to specific allergen components or epitopes (e.g., Ara h 2 for peanut, bead-based epitope assays) to refine diagnostic accuracy

Clinical utilityComponent testing (e.g., Ara h 2) can have superior diagnostic accuracy for peanut compared with whole-extract testing and may reduce need for challenges

GuidanceUse selectively based on clinical history and pretest probability rather than routinely in addition to SPT or whole-extract sIgE

Basophil activation test (BAT) — functional assay

DefinitionFunctional in vitro assay measuring basophil activation markers (CD63, CD203c) after allergen stimulation to assess reactivity and sensitivity

Diagnostic performanceStudies report high accuracy for peanut allergy and capability to predict severity and reaction thresholds

Role in care pathwayMay be useful in two-step diagnostic approaches after equivocal SPT or sIgE to reduce oral food challenges

sIgE

DefinitionSerum allergen-specific immunoglobulin E (sIgE); indicates sensitization and is useful when SPT cannot be performed

LimitationssIgE indicates presence of antibody but is not solely diagnostic of clinical allergy; results require clinical correlation

Use casesAlternative to SPT for patients with widespread dermatitis, dermatographism, or who cannot stop antihistamines

BAT — Clinical consideration

DefinitionBasophil Activation Test (BAT) — an option when first-line tests are inconclusive; measures basophil markers after allergen exposure

Standardization statusCurrently considered nonstandardized in some guidelines and limited by laboratory variability; requires further standardization for routine use

Suggested useConsider in specialized labs or as part of a stepwise approach when SPT/sIgE are equivocal

Molecular (component-resolved) diagnostics

DefinitionPrecision allergy molecular diagnostics (component-resolved testing) detect IgE to specific allergenic molecules to refine risk assessment

BenefitsCan improve accuracy in select circumstances (assessing risk, identifying triggering components) per WAO/ARIA/GA2LEN consensus

Use guidanceUse selectively to answer focused diagnostic questions; not routine for broad screening

Laboratory-developed test (LDT)

DefinitionLaboratory-developed test (LDT): an in-house test developed and validated by a laboratory and regulated under CLIA as high-complexity; not FDA-cleared

Regulatory implicationLDTs are regulated by CMS under CLIA '88 and may affect reimbursement determinations; FDA clearance is not required for clinical use

DocumentationPolicy requests documentation indicating whether an assay is FDA-cleared or is an LDT and its CLIA classification

OpenPayer

Allergen Testing

Coverage Criteria for Allergen Testing

Coding and Quantity Limits

Provider Actions, Documentation, and Billing Guidance

Definitions and Test Descriptions

Clinical Background and Evidence Summary

Evidence, Performance Metrics, and References